Fragmento

Validation and comparison of simple noninvasive models for the prediction of liver fibrosis in chronic hepatitis C. Fenili Amorim, et al. Evaluation of liver fibrosis is of key importance in the management of patients with hepatitis C virus (HCV) as it helps guide therapy and serves as a prognostic marker of the disease. International guidelines recommend prompt initiation of antiviral therapy in patients with HCV and advanced fibrosis (METAVIR F3-F4) and recommend that treatment should be strongly considered in patients with METAVIR F2. Liver biopsy has been classically considered the gold standard to evaluate liver fibrosis. However, biopsy presents several limitations such as sampling error, intra- and inter-observer variability, and the possibility of infrequent but potentially life-threatening complications. These limitations have led in recent years to the development of noninvasive methods to assess liver fibrosis. Among these, indirect serologic markers are routine, easy-to-perform and inexpensive serum tests that allow, alone or in combination, to identify patients with advanced stages of liver fibrosis.

Palabras clave:

2012-11-14   |   453 visitas   |   Evalua este artículo 0 valoraciones

Vol. 11 Núm.6. Noviembre-Diciembre 2012 Pags. 816-818 Ann Hepatol 2012; 11(6)